Table 1

- Baseline characteristics and comorbidities according to antihypertensive drug.

Total	Age (years)	Male, n (%)	Prescription days, median (Q1, Q3)	Comorbidities, n (%)
Total	Age (years)	Male, n (%)	Prescription days, median (Q1, Q3)	Auto immune	Heart failure	Dementia	Diabetes	Cancer	CKD
ARBs (n=21,820)	63.1 ± 13.6^a	12,465 (57.1)	77 (14, 497)^a	168 (0.8)^a	1,542 (7.8)	727 (3.3)^a	5,271 (24.2)^a	1,469 (6.7)^a	2,657 (12.2)
Olmesartan (n=1,995)	63.6 ± 13.3^a,b	1,122 (56.2)^b,c,d	35 (7, 271)^d	10 (0.5)^a,b	118 (5.9)^a,b	70 (3.5)^a,b,c,d	375 (18.8)^b,c	174 (8.7)^g	207 (10.4)^d,e,f
Candesartan (n=6,650)	63.2 ± 13.4^a,b	4,036 (60.7)^a	94 (14, 713)^b	32 (0.5)^b	83 (12.5)^c	199 (3.0) ^a,b,c,d	1,723 (25.9)^a	357 (5.4)^e,f,h	797 (12.0)^f
Fimasartan (n=3,005)	63.7 ± 12.8^a,b	1,803 (60.0)^a,d	82 (15, 403)^a,b	16 (0.5)^a,b	86 (2.9)^d	128 (4.3)^c,d	570 (19.0)^b,c	127 (4.2)^h	153 (5.1)^c
Irbesartan (n=2,021)	63.4 ± 12.7^a,b	1,062 (52.5)^b,c	99 (21, 573)^b	10 (0.5)^a,b	72 (3.6)d	88 (4.4)^b,d	575 (28.5)^a	117 (5.8)^c,d,f,h	169 (8.4)^b,d
Losartan (n=3,300)	62.6 ± 15.6^a,b	1,750 (53.0)^b,c	56 (9, 405)^a,c	71 (2.2)	145 (4.4)^b,d	106 (3.2)^a,b,c,d	662 (20.1)^c	293 (8.9)^b,g	551 (16.7)^g,h
Telmisartan (n=2,030)	61.8 ± 13.4^a	1,118 (55.1)^b,c	49 (8, 407)^a,c	16 (0.8)^a,b	73 (3.6)^d	45 (2.2)^a,e	544 (26.8)^a	170 (8.4)^b,d,g	266 (13.1)^e,f,h
Valsartan (n=2,819)	63.4 ± 13.7^a,b	1,574 (55.8)^b,c,d	54 (10, 357)^a,c	23 (0.8)^a,b	332 (11.8)^c	91 (3.2)^a,b,c,d	822 (29.2)^a	231 (8.2)^b,d,g	514 (18.2)^g
ACEI (n = 1,297)	62.7 ± 14.5^a	843 (65.0)	67 (9, 470)^a	8 (0.6)^a	289 (22.3)	34 (2.6)^a,b	325 (25.1)^a	95 (7.3)^a	98 (7.6)
Ramipril (n = 1,297)	62.7 ± 14.5^a	843 (65.0)^a	67 (9, 470)^a	8 (0.6)^a,b	289 (22.3)	34 (2.6)^a,b,c,d	325 (25.1)^a	95 (7.3) ^{a,b,c,d,e,f,g}	98 (7.6)^a,b,c,d
CCB (n=6,769)	64.8 ± 13.2	3,523 (52.0)	22 (3, 175)	35 (0.5)^a	79 (1.2)	219 (3.2)^a	855 (12.6)	699 (10.3)	381 (5.6)
Amlodipine (n=6,769)	64.8 ± 13.2	3,523 (52.0)^c	22 (3, 175)	35 (0.5)^a,b	79 (1.2)	219 (3.2)^a,b,c,d	855 (12.6)	699 (10.3)^b,g	381 (5.6)^a,c
BBs (n=4,889)	54.3 ± 16.1	7,452 (50.1)	23 (1, 149)	115 (0.8)^a	359 (2.4)	252 (1.7)^b	1,488 (10.0)	541 (3.6)	350 (2.4)
Bisoprolol (n=4,284)	62.9 ± 14.4^a,b	2,424 (56.6)^b,d	31 (8, 306)^d	18 (0.4)^b	308 (7.2)^a	92 (2.1)^a	691 (16.1)^b	249 (5.8)^a,c,e,f,h	228 (5.3)^a,c
Propranolol (n=10,605)	50.8 ± 15.4	5,028 (47.4)	15 (1, 103)	97 (0.9)^a	51 (0.5)	160 (1.5)^e	797 (7.5)	292 (2.8)	122 (1.2)
Total (N= 44,775)	60.4 ± 15.1	24,283 (54.2)	35 (7, 312)	336 (0.8)	2,387 (5.3)	1,232 (2.8)	7,939 (17.7)	2,804 (6.3)	3,486 (7.8)

Values are mean ± SD (age), median (Q1, Q3) (prescription days), or number (%). The analysis was conducted separately for antihypertensive drug classes and individual antihypertensive drugs. The same superscript lowercase letters indicate no statistical significance between the groups being compared: ANOVA and Duncan’s post hoc test or Kruskall-Wallis H test and Duncan’s post hoc test for continuous variables and Chi-square test and Bonferrini’s post hoc test for categorical variables. ACEI: angiotensin-converting enzyme inhibitor, ARBs: angiotensin receptor blockers, CCB: calcium channel blocker, BBs: beta-blockers, CKD: chronic kidney disease